|Awarded On||August 24, 2018|
|Title||Cyanine-Conjugated Kinase Inhibitors (Cy-KIs) as Potential Glioblastoma Theranostics|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas A&M University System Health Science Center|
|Principal Investigator/Program Director||Raquel Sitcheran|
|Cancer Sites||Brain and Other Nervous System|
Drugs called “kinase inhibitors” (KIs) are extremely effective in treating several cancers, but notable exceptions are brain cancers, including the most common and deadly adult brain tumor, glioblastoma (GBM). KIs have been unsuccessful for treating GBM because they do not effectively reach the brain due to limited permeability though the blood-brain barrier (BBB), which separates the blood system from the brain. Additionally, drugs that can cross the BBB tend to be actively pumped back out. Another obstacle to effectively treating GBMs is the difficultly in complete surgical removal due to their aggressive invasion into healthy brain tissue. Indeed, the high invasiveness of GBMs is a major...